EULAR guidelines--as well as ACR recommendations for RA management--are relatively agnostic as far as which biologic DMARD should be used to intensify RA therapy after a methotrexate or other synthetic DMARD failure. What factors do you consider when deciding whether an IL-6 inhibitor is the best option?

EULAR guidelines--as well as ACR recommendations for RA management--are relatively agnostic as far as which biologic DMARD should be used to intensify RA therapy after a methotrexate or other synthetic DMARD failure. What factors do you consider when deciding whether an IL-6 inhibitor is the best option?

The new EULAR guidelines—as well as ACR recommendations for RA management—are relatively agnostic as far as which biologic DMARD should be used to intensify RA therapy after a methotrexate or other synthetic DMARD failure. What factors do you consider when deciding whether an IL-6 inhibitor is the best option?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Roy Fleischmann, MD

Roy Fleischmann, MD

Clinical Professor of Medicine University of Texas Southwestern Medical Center at Dallas Co-Director, Division of Rheumatology Texas Health Presbyterian Medical Center and Co-Medical Director Metroplex Clinical Research Center